key: cord-1042677-5y980oov
authors: Agrawal, Manasi; Zhang, Xian; Brenner, Erica J; Ungaro, Ryan C; Kappelman, Michael D; Colombel, Jean-Frederic
title: The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry
date: 2021-04-22
journal: J Crohns Colitis
DOI: 10.1093/ecco-jcc/jjab071
sha: 768e4c53cc298ae9f563aa7a4fc293ed07c644f6
doc_id: 1042677
cord_uid: 5y980oov

INTRODUCTION: The impact of immune-modifying therapies on outcomes of Coronavirus disease of 2019 (COVID-19) is variable. The purpose of this study was to determine the impact of vedolizumab (VDZ), a gut-selective anti-integrin, on COVID-19 outcomes in inflammatory bowel disease (IBD) patients. METHODS: Using data from the Surveillance of Coronavirus Under Research Exclusion for IBD (SECURE-IBD), an international registry of IBD patients with confirmed COVID-19, we studied the impact of VDZ on COVID-19 hospitalization and severe COVID-19 (intensive care unit stay, mechanical ventilation and/or death). RESULTS: Of 3,647 adult patients on any IBD medication in the registry, 457 (12.5%) patients were on VDZ. On multivariable analyses using backward selection of covariates, VDZ use was not associated with hospitalization or severe COVID-19 when comparing to patients on all other medications [adjusted odds ratio (aOR) 0.87; 95% confidence interval (CI) 0.71, 1.1 and aOR 0.95; 95% CI 0.53; 1.73, respectively]. On comparing VDZ monotherapy to anti-TNF monotherapy, the odds for hospitalization, but not severe COVID-19, were higher (aOR CI 1.39; 95% CI 1.001, 1.90 and aOR 2.92; 95% CI 0.98, 8.71, respectively). In an exploratory analysis, VDZ monotherapy, compared to anti-TNF monotherapy, was associated with new-onset GI symptoms at the time of COVID-19, especially among patients whose IBD was in remission. CONCLUSIONS: COVID-19 outcomes among IBD patients on VDZ are comparable to those on all other therapies. Hospitalization, but not severe COVID-19, is more likely with VDZ monotherapy than with anti-TNF monotherapy. Overall, VDZ appears to be safe in IBD patients with COVID-19.

The impact of immune-modifying therapies on outcomes of Coronavirus disease of 2019 (COVID-19) is variable. The purpose of this study was to determine the impact of vedolizumab (VDZ), a gut-selective anti-integrin, on COVID-19 outcomes in inflammatory bowel disease (IBD) patients.

Using data from the Surveillance of Coronavirus Under Research Exclusion for IBD (SECURE-IBD), an international registry of IBD patients with confirmed COVID-19, we studied the impact of VDZ on COVID-19 hospitalization and severe COVID-19 (intensive care unit stay, mechanical ventilation and/or death).

Of 3,647 adult patients on any IBD medication in the registry, 457 (12.5%) patients were on VDZ. On multivariable analyses using backward selection of covariates, VDZ use was not associated with hospitalization or severe COVID-19 when comparing to patients on all other medications [adjusted odds ratio (aOR) 0.87; 95% confidence interval (CI) 0.71, 1.1 and aOR 0.95; 95% CI 0.53; 1.73, respectively]. On comparing VDZ monotherapy to anti-TNF monotherapy, the odds for hospitalization, but not severe COVID-19, were higher (aOR CI 1.39; 95% CI 1.001, 1.90 and aOR 2.92; 95% CI 0.98, 8 .71, respectively). In an exploratory analysis, VDZ monotherapy, compared to anti-TNF monotherapy, was associated with newonset GI symptoms at the time of COVID-19, especially among patients whose IBD was in remission.

Conclusions COVID-19 outcomes among IBD patients on VDZ are comparable to those on all other therapies. Hospitalization, but not severe COVID-19, is more likely with VDZ monotherapy than with anti-TNF monotherapy. Overall, VDZ appears to be safe in IBD patients with COVID-19.

The coronavirus disease 2019 (COVID-19) pandemic due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unrelenting pandemic, affecting over 85 million persons globally with 2.32 million deaths until February 8, 2021 (1) . Comorbid disease is a risk factor for worse outcomes (2) , and medications that modulate the immune system can have varying effects on COVID-19, depending on their mechanism of action. SARS-CoV-2, in addition to infecting the respiratory epithelium, can also infect the gastrointestinal (GI) tract mucosa via angiotensin converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TRMPRSS) (3) . In addition to upper and lower respiratory symptoms, COVID-19 can be associated with GI symptoms such as anorexia, vomiting and diarrhea (4). Vedolizumab (VDZ), a monoclonal antibody against integrin, blocks the interaction between 4 7 integrin on CD4+ T cells and its receptor mucosal addressin cell adhesion molecule (MAdCAM) on high endothelial venules (HEV) in the GI tract, with downstream blockage of lymphocyte trafficking into gut-associated lymphoid tissue (GALT), (5) . VDZ is approved for the treatment of moderate-severe ulcerative colitis (UC) and Crohn's disease (CD) in adult patients (5, 6) . Given its gut-specific mechanism of action, VDZ does not impact systemic immunity significantly and has a favorable safety profile (7) . However, VDZ is associated with an increased risk of Clostridium difficile and other intestinal infections (8) . Recent data report that VDZ may modulate ACE2 expression in the GI tract (9) .

We aimed to determine the outcomes of COVID-19 infection among IBD patients on VDZ compared to other IBD therapies. We also determined the proportion of IBD patients on VDZ who had new-onset GI symptoms at the time of COVID-19.

The Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry is a global, web-based, collaborative database, which was established at the start of the COVID-19 pandemic in March 2020 to study characteristics and outcomes in IBD patients with confirmed COVID-19, as well as the impact of IBD therapies (10) . Healthcare providers voluntarily report confirmed COVID-19 cases using a REDCap (Research Electronic Data Capture) survey at our website covidibd.org, hosted at the University of North Carolina. SECURE-IBD collects only deidentified data, and the Office of Human Research Ethics at the University of North Carolina, Chapel Hill determined that the storage and analysis of de-identified data for this project did M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjab071 6 not constitute human subjects research. Details of the data collection and quality control are described in detail in a previous publication (10) .

Using data reported though January 26, 2021, we compared baseline and demographic characteristics, and COVID-19 outcomes of adult IBD patients on VDZ therapy to those on all other IBD medications. As VDZ is approved for treatment of adult IBD patients only, we excluded patients ≤18 years of age from this analysis. Our primary outcome was adverse COVID-19, defined as hospitalization or death due to COVID-19. Our secondary outcome was severe COVID-19 defined as a composite of intensive care unit (ICU) admission, mechanical ventilation and/or death. We compared all outcomes among adult patients on VDZ vs all other IBD therapies in the registry (VDZ vs. non-VDZ). As the category of all other medications is heterogenous, we additionally compared VDZ monotherapy with anti-tumor necrosis factor (TNF) monotherapy, which is the largest homogenous category of reported medications in the registry. Lastly, as an exploratory analysis, we compared the frequency of GI symptoms due to COVID-19 between VDZ and non-VDZ groups as well as between VDZ monotherapy and anti-TNF monotherapy groups.

We analyzed categorical variables using Chi-square or Fisher-Exact tests, and continuous variables using Wilcoxon rank-sum or t-test when applicable. Using generalized estimating equations (GEE) to account for clustering by country, and applying the logit link function, we estimated the odds of each of the two binary outcomes, adverse and severe COVID-19. In addition to the primary predictor variable medication group, covariates in each of the models were determined by backward selection to obtain the most parsimonious models from clinically-relevant covariates determined a priori, or if associated with medication group at p value ≤0.10 level on bivariate analysis. Considered covariates included age, sex, race/ethnicity, IBD type, IBD activity [remission vs active disease, based on physician global assessment (PGA)] and comorbidities (0, 1, ≥2). Additionally, as IBD activity may modify the association between treatment and each study outcome, and treatment and GI symptoms, we repeated all analyses stratified by IBD activity categorized as remission versus active disease. P values ≤0.05 were considered statistically significant for all analyses. Data preparation and analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North Carolina).

Of 3,647 patients ≥18 years old in the SECURE-IBD registry on one or more IBD medication, 457 (12.5%) patients were reported to be on VDZ, of whom 334 (9.2%) were on VDZ monotherapy. 1043 (28.6%) patients were on an anti-TNF monotherapy. Of these, 536 (51.4%) patients were on an intravenous anti-TNF while the remaining 507 (48.6%) patients were on a subcutaneous anti-TNF. 354 (9.7%) patients were on combination therapy with an M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjab071 7 anti-TNF and an immunomodulator. The baseline demographic and clinical characteristics of all patients in VDZ vs. non-VDZ groups are reported in Table 1 . Compared to the non-VDZ group, patients on VDZ were slightly older (mean age 43.8 years vs 42.0 years, p=0.03), more likely to be white (86.0% vs 81.2%, p=0.01) and less likely to be Asian or Hispanic (1.8% vs. 5.0%, p=0.002 and 10.9% vs 14.9%, p<0.001, respectively). Of patients on VDZ, 209 (45.7%) were from the United States, whereas of those on other therapies, 1110 (34.8%) were from the United States (p<0.001). Compared to the non-VDZ group, more patients in the VDZ group had UC (53.8% vs 40.2%, p<0.001). Other baseline and clinical characteristics were similar between the two groups. Baseline characteristics of VDZ monotherapy compared to anti-TNF monotherapy are reported in the supplementary table.

Six hundred and sixty-four hospitalization and 166 severe COVID events occurred in the cohort. Compared to non-VDZ use, VDZ use was not associated with hospitalization [adjusted odds ratio (aOR) 0.87; 95% confidence interval (CI) 0.71, 1.1, Table 2 ] after adjusting for age, Asian and Other race/ethnicity groups compared to non-Hispanic White group, IBD type, sex and number of comorbidities. Similarly, compared to non-VDZ use, VDZ use was not associated with severe COVID-19 (aOR 0.95; 95% CI 0.53, 1.73) on adjusting for age, IBD type, comorbidities and IBD activity. Upon stratifying by IBD activity (active disease vs remission), the results were not significantly altered. In the stratum of active IBD, compared to non-VDZ use, VDZ use was not associated with hospitalization (aOR 0.95; 95% CI 0.72, 1.25) or severe COVID-19 (aOR 0.91; 95% CI 0.46, 1.81). Similarly, in the stratum of IBD remission, compared to non-VDZ use, VDZ was not associated with hospitalization (aOR 0.84; 95% CI 0.61, 1.15) or severe COVID-19 (aOR 1.40; 95% CI 0.53, 3.67).

Upon comparing to anti-TNF monotherapy, VDZ monotherapy was associated with higher odds of hospitalization (aOR 1.38; 95% CI 1.001, 1.90, Table 2 ) after adjusting for age, number of comorbidities, Asian and Other races compared to non-Hispanic White group and IBD activity. The magnitude and direction of the association of VDZ monotherapy, compared to anti-TNF monotherapy, with severe COVID-19 outcomes were similar but not statistically significant after adjusting for age and number of comorbidities (aOR 2.92; 95% CI 0.98, 8.71). Upon stratifying by IBD activity, results remained similar in magnitude and direction. The association of VDZ monotherapy with hospitalization was not significant in the stratum of active IBD (aOR 1.32; 95% CI 0.75, 2.33), but it was significant in the stratum of IBD in remission (aOR 1.54; 95% CI 1.05, 2.25). The number of severe COVID-19 outcomes in the VDZ and anti-TNF monotherapies groups were too few for stratified analyses.

All GI symptoms (nausea, vomiting, abdominal pain, diarrhea and "other") were comparable between VDZ and non-VDZ groups (p >0.05), Table 3 ). On stratifying by IBD activity, all GI symptoms were comparable in both strata except nausea, which was more common with VDZ in those with IBD in remission (8.8% vs 4.4%, p=0.004). M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjab071 8 On comparing VDZ monotherapy with anti-TNF monotherapy, all GI symptoms except other symptoms were more common with VDZ monotherapy (p <0.05 for each comparison). When we stratified these comparisons by IBD activity, among patients with active IBD, all GI symptoms were similar in frequency with VDZ and anti-TNF monotherapies. Among IBD patients in remission, all GI symptoms, except vomiting and other, were more common with VDZ monotherapy (p ≤0.001 for each comparison except vomiting and other).

In this analysis of 3,647 adult patients from 63 countries in the SECURE-IBD registry, we report COVID-19 outcomes among 457 patients on VDZ therapy compared to other IBD therapies. Overall, we observed comparable COVID-19 outcomes among IBD patients on VDZ versus those on all other therapies. New-onset GI symptoms were reported in 29.6% of patients on VDZ monotherapy and 19.2% of patients on anti-TNF monotherapy. Hospitalization and the development of GI symptoms were more frequently observed with VDZ monotherapy than with anti-TNF monotherapy.

Hospitalization and severe COVID-19 outcomes were comparable among VDZ and non-VDZ users, unchanged upon stratification by IBD activity. These findings are consistent with other data on COVID-19 outcomes among IBD patients on VDZ, although there are few such patients in each of these analyses. Lukin, Kumar et al reported in a case-control study that COVID-19 outcomes of patients on all biologic therapies, including VDZ (n=10), were comparable, although VDZ was not studied individually (11) . Similarly, Axelrad et al reported in a descriptive case series that there were no differences in outcomes among patients on VDZ (n=5) compared to other IBD therapies (12) . Given the gut-selective mechanism of action of VDZ and lack of significant systemic adverse effects (7), its safety in patients with COVID-19 is reassuring. It is important to note that the comparator, non-VDZ group is heterogenous and includes patients on all other medications such as 5-aminosalisylic acid, corticosteroids, immunomodulators, biologics and combination therapies, each of which can have varying impact on COVID-19 outcomes (13) .

In order to characterize the impact of VDZ in more homogenous medication groups, we additionally compared COVID-19 outcomes among patients on VDZ monotherapy to those on anti-TNF monotherapy. In adjusted analyses, hospitalization was 38% more likely to occur with VDZ monotherapy compared to anti-TNF monotherapy. There was no difference in severe COVID-19 between the two groups, but the direction of the effect was consistent with that of hospitalization. These findings may reflect a potentially protective effect of anti-TNF therapy, as demonstrated in previous data from our registry (13) and other emerging studies (14, 15 ). Data on mucosal gene expression suggest downregulation of ACE2 in UC patients who respond to TNFi, but not in patients treated with VDZ (16) . Furthermore, VDZ M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjab071 9 mediated attenuation of lymphocyte aggregates in the GI tract may explain these findings, at least in part (17) .

As an exploratory analysis, we also noted that new-onset GI symptoms in IBD patients with COVID-19, while reported in a minority of patients, were similar in frequency in patients on VDZ, when compared to other therapies overall. With stratification by IBD activity, nausea, but not other symptoms, was more common among patients in remission and on VDZ. However, compared to patients on anti-TNF monotherapy, patients on VDZ monotherapy more frequently experienced most GI symptoms. Upon stratification by IBD activity, GI symptoms tended to be more common among patients on VDZ who were in remission. However, the number of patients reporting GI symptoms due to COVID-19 in each subgroup is few, making clinically meaningful interpretation difficult. The higher frequency of GI symptoms in VDZ-treated patients, as compared to anti-TNF treated patients, may partially explain the higher odds of hospitalization in VDZ-treated patients.

Our study has several strengths. We have data on COVID-19 outcomes on close to 3,500 adult IBD patients in a large collaborative registry of IBD patients from 63 different countries on diverse IBD medications, of which more than 450 patients were on VDZ. This is the largest report of COVID-19 outcomes among patients on VDZ therapy. Limitations of this voluntary registry include the risk of reporting bias, which may lead to documentation of the more severe cases that come to the attention of healthcare providers, while the milder cases may remain undiagnosed or underreported. Conversely, frequently tested asymptomatic patients may be diagnosed incidentally. However, given the large sample size and representation of patients in various subgroups, this is less likely. Other limitations include unmeasured confounding, risk of misclassification of the cause of GI symptoms (IBD vs COVID-19) and missing data, although the latter was <4% for all variables except ethnicity and body mass index.

In conclusion, COVID-19 outcomes among IBD patients on VDZ are comparable to those on other therapies. Hospitalization, but not severe COVID-19, is slightly more likely with VDZ monotherapy than with anti-TNF monotherapy, possibly due to higher frequency of GI symptoms with VDZ. These findings reiterate the overall safety of VDZ in IBD patients with COVID-19. M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

COVID-19 Dashboard by the Center for Systems Science and Engineering

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD

Are Gastrointestinal Symptoms Specific for Coronavirus 2019 Infection? A Prospective Case-Control Study From the United States

Vedolizumab as induction and maintenance therapy for ulcerative colitis

Vedolizumab as induction and maintenance therapy for Crohn's disease. The New England journal of medicine

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease

Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area. Inflammatory bowel diseases

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the rheumatic diseases

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the rheumatic diseases

Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

Anti-alpha4beta7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals